Pediatric collagenous gastritis

Summary

Pediatric collagenous gastritis (MONDO:0044624) is a disease. A subtype of gastritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		24	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	pediatric collagenous gastritis
Mondo ID	MONDO:0044624
Orphanet	487809
UMLS	C5680109
MedGen	1805938
GARD	0021998
Is cancer (heuristic)	no

Also known as: childhood-onset collagenous gastritis

Disease family

This is a subtype of gastritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › stomach disorder › gastritis › pediatric collagenous gastritis

Related subtypes (15): gastroduodenal Crohn disease, viral gastritis, eosinophilic gastritis, bacterial gastritis, fungal gastritis, lymphocytic gastritis, necrotizing gastritis, granulomatous gastritis, gastroduodenitis, alcoholic gastritis, chronic gastritis, gastric mucosal hypertrophy, chronic erosive gastritis, autoimmune gastritis, collagenous gastritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.